Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.65 |
| ▸ | TXNRD1 | Q16881 | 16/20 | 0.50 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.46 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | GFER | P55789 | 1/20 | 0.46 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | GSR | P00390 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4305170 | 0.89 | TXNRD1 (0.56) | MAPTTXNRD1S1PR4S1PR1MAPK1 | |
| SCHEMBL9694197 | 0.85 | LMNA (0.50) | MAPTTXNRD1GSR | |
| SCHEMBL4311846 | 0.84 | TXNRD1 (0.48) | MAPTTXNRD1S1PR4S1PR1MAPK1 | |
| SCHEMBL28489675 | 0.83 | TXNRD1 (0.57) | MAPTTXNRD1S1PR4S1PR1MAPK1 | |
| SCHEMBL9794246 | 0.82 | TXNRD1 (0.53) | MAPTTXNRD1S1PR4S1PR1MAPK1 | |
| SCHEMBL13728591 | 0.82 | TXNRD1 (0.46) | MAPTTXNRD1S1PR4S1PR1MAPK1 | |
| SCHEMBL10654754 | 0.81 | TXNRD1 (0.55) | MAPTTXNRD1S1PR4S1PR1MAPK1 | |
| SCHEMBL5832677 | 0.81 | TXNRD1 (0.63) | MAPTTXNRD1RAB9AGSR | |
| SCHEMBL3403683 | 0.80 | TXNRD1 (0.57) | MAPTTXNRD1S1PR4S1PR1MAPK1 | |
| SCHEMBL13728584 | 0.80 | TXNRD1 (0.48) | MAPTTXNRD1S1PR4S1PR1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | claimed |
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | MERCK SHARP & DOHME CORP. | 2009-03-05 | — | — | US | disclosed |
| EP-2004193-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | Merck & Co., Inc. (US) | 2008-12-24 | — | — | EP | disclosed |
| WO-2007108968-A2 | OPHTHALMIC COMPOSITIONS FOR TREATING OCULAR HYPERTENSION | MERCK & CO., INC. (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090062280-A1 | Ophthalmic Compositions for Treating Ocular Hypertension | KCNN3, KCNN1, KCNN2 | MAPT 498/4885TXNRD1 735/4885S1PR4 1742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.